Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 前沿生物药业（南京）股份有限公司成立于2013年，致力于研究、开发、生产及销售针对未满足的重大临床需求的创新药。公司是抗病毒创新药研究领域的先驱企业，尤其在HIV长效治疗及免疫治疗细分领域具有国际竞争力，并已形成了立足中国、面向全球的国际化商业格局。 公司拥有先进的长效多肽技术平台及新型透皮贴片制剂技术平台。2018年公司自主研发的国家1类抗HIV新药艾可宁（通用名：艾博韦泰）获批上市，目前在研产品管线包括抗HIV长效创新联合疗法FB1002、抗新型冠状病毒新药FB2001、治疗肌肉骨骼疼痛新型透皮贴片FB3001、治疗性长效降血脂新药FB6001，治疗骨质疏松产品FB4001，及其他储备项目。 公司于2020年10月在上海证券交易所科创板挂牌上市（股票代码：688221.SH），上市以来先后获得“2020年荣登中国医药新锐创新力量十强企业”、“2021年度科创板最具投资价值企业”、“2022年度生物科技创新奖”、“第二十四届中国专利金奖”等商业殊荣。 公司成立以来，坚守“以患者为中心，创新解决方案，促进人类健康”的核心价值观，积极布局前瞻性的产品科研工作。结合商业发展需求，建设国内和海外一流的研发、生产、医学推广、市场开拓的专业团队，旨在成为全球领先的生物制药企业。 前沿生物药业（南京）股份有限公司经过十余载的研发积累，目前已经建立了完整的新药研发体系，形成了创新药物研发方面的核心竞争力，包括药物分子设计和发现、临床方案的设计与实施、法规市场药品的注册与获批、生产工艺放大与质量管控等各个核心环节。 立足产业化实力提升，公司在南京江宁、四川金堂、山东齐河分别打造符合美国FDA、欧盟EMA和中国NMPA认证的国际化制造体系的制剂、原料药生产基地，定位面向全球市场，为公司业务体系发展实现商业化、国际化提供坚实基础。 全面加快商业化转型，公司在国内同领域已搭建覆盖医疗机构广泛、深入的营销体系，同时积极开拓创新药产品的全球市场渠道。深耕国内市场，已上市的产品于2020年被纳入国家医保药品目录，产品销量稳步提升，为公司业绩稳步增长奠定基础。开拓海外市场，公司在全球多国开启商业化产品注册、上市等工作，目前艾可宁分别在厄瓜多尔、柬埔寨、阿塞拜疆、马来西亚获批上市，并医学紧急出口俄罗斯、南非。在2021年重大新药创制科技重大专项“十三五”科技创新成就展上，艾可宁?作为为数不多的代表性新药被展出。
Main Business 针对抗病毒和肌肉骨骼疼痛治疗药物的研发、生产和销售业务。
Legal Representative 谢东
Top Executives
董事长：谢东
董事：陈远帆,陆荣健,王昌进
独立董事：吴智杰,陈凯,王广基
Top 5 Shareholder
Shareholder name Nature Holding Date
建木藥業有限公司流通A股18.86%30/09/2024
LU RONGJIAN流通A股5.80%30/09/2024
WANG CHANGJIN流通A股5.62%30/09/2024
南京建木商务咨询合伙企业（有限合伙）流通A股4.59%30/09/2024
南京建木生物技术有限公司流通A股3.72%30/09/2024
Company Secretary 高千雅
Solicitors 国浩律师(南京)事务所
Auditors 毕马威华振会计师事务所(特殊普通合伙)
Tel No 025-69648375
Fax No 025-69648373
Website www.frontierbiotech.com
Email invest@frontierbiotech.com
Company Address
Register: 江苏省南京市江宁区科学园乾德路5号7号楼（紫金方山）
Office: 南京市江宁区东山街道绿地之窗E-2栋11层
Listing Date 28/10/2020
Shares Capital
Shares Capital: 374,578,653
Total A Share: 374,578,653
Listed A Share: 374,578,653
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.880
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 3.585
Market Capitalization(RMB) 2.899B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.